Showing 1441-1450 of 1621 results for "".
- UK to Test “Subscription-Style” Payment Model in Effort to Spur Development of New Antibioticshttps://modernod.com/news/uk-to-test-subscription-style-payment-model-in-effort-to-spur-development-of-new-antibiotics/2476717/The NHS will test a “subscription-style” payment model for antibiotics as part of efforts by the UK government to incentivise companies to develop new medicines to tackle drug-resistant infections. Under the proposed scheme, the Department of Health and Social Care said Tuesday that d
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- Aerie Pharmaceuticals Matches ASCRS Foundation Fund Raising to Provide Sight-Saving Surgeryhttps://modernod.com/news/aerie-pharmaceuticals-matches-ascrs-foundation-fund-raising-to-provide-sight-saving-surgery/2476538/Aerie Pharmaceuticals announced that it is matching, dollar for dollar, the first $30,000 donated to the ASCRS Foundation’s charitable eye care programs by attendees at the 2019 ASCRS-ASOA Annual Meeting, being held in San Diego, from May 3-7, 2019. This is the second year that Aerie is d
- Clinical Trials Show Safety and Efficacy of Inveltys for BID Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/clinical-trials-show-safety-and-efficacy-of-kala-pharmaceuticals-inveltys-for-bid-treatment-of-postoperative-inflammation-and-pain/2476380/Kala Pharmaceuticals announced publication of two multicenter, randomized, double-masked, vehicle-controlled clinical trials of Inveltys (loteprednol etabonate ophthalmic suspension 1%) for treatment of inflammation and pain following cataract surgery. Inveltys, which utilizes AMPPLIFY D
- Dompé Receives Industry Innovation Award for Oxervate Eye Drops for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-industry-innovation-award-for-oxervate-eye-drops-for-neurotrophic-keratitis/2476372/Dompé Farmaceutici S.p.A and Dompé US Inc. announced that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefiting rare d
- Gottlieb’s Quick Goodbye Triggers Investor Panic, Biopharma Bewildermenthttps://modernod.com/news/gottliebs-quick-goodbye-triggers-investor-panic-biopharma-bewilderment/2476360/When FDA Commissioner Scott Gottlieb got his job, critics called him a shill and industry types figured they’d gained a friend in the most important drug regulatory agency in the world. It didn’t turn out quite that way. Gottlieb was biopharma-friendly—to the point where the Na
- Bruder Announces Eyeleve Contact Lens Compresshttps://modernod.com/news/bruder-announces-eyeleve-contact-lens-compress/2479603/Bruder Healthcare announces the immediate availability of Eyeleve, a compress clinically proven to increase comfortable contact lens wear time by up to 3 hours daily. The Eyeleve Contact Lens Compress delivers consistent, therapeutic moist heat that alleviates symptoms of meibomian gland d
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Notal Vision Engages Wasatch Photonics Bringing AI-Enabled Home-Based OCT Closer to Markethttps://modernod.com/news/notal-vision-engages-wasatch-photonics-bringing-ai-enabled-home-based-oct-closer-to-market/2479605/Notal Vision has announced the achievement of a significant milestone in its plan to develop and commercialize a home-based, patient-operated, spectral-domain optical coherence tomography (SD-OCT) system. The first targeted application of the Notal Home OCT is to monitor wet age-related macular d
- RayOne Aspheric Fully Preloaded IOL Receives FDA Clearancehttps://modernod.com/news/rayone-aspheric-fully-preloaded-iol-receives-fda-clearance/2479618/Rayner announced that the FDA has cleared the RayOne Aspheric fully preloaded IOL injection system for use in the United States. The FDA granted regulatory clearance of the RayOne Aspheric Monofocal (RAO600C), a fully preloaded aberration-neutral IOL covering a power range of +8.0 D to +34